Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

122 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase I study of adjuvant gemcitabine or S-1 in patients with biliary tract cancers undergoing major hepatectomy: KHBO1003 study.
Kobayashi S, Nagano H, Sakai D, Eguchi H, Hatano E, Kanai M, Seo S, Taura K, Fujiwara Y, Ajiki T, Takemura S, Kubo S, Yanagimoto H, Toyokawa H, Tsuji A, Terajima H, Morita S, Ioka T. Kobayashi S, et al. Among authors: toyokawa h. Cancer Chemother Pharmacol. 2014 Oct;74(4):699-709. doi: 10.1007/s00280-014-2543-4. Epub 2014 Jul 30. Cancer Chemother Pharmacol. 2014. PMID: 25074036 Clinical Trial.
A phase I study for adjuvant chemotherapy of gemcitabine plus S-1 in patients with biliary tract cancer undergoing curative resection without major hepatectomy (KHBO1202).
Yanagimoto H, Toyokawa H, Sakai D, Wada H, Satoi S, Yamamoto T, Nagano H, Toyoda M, Ajiki T, Satake H, Tsuji A, Miyamoto A, Tsujie M, Takemura S, Yanagihara K, Ioka T. Yanagimoto H, et al. Among authors: toyokawa h. Cancer Chemother Pharmacol. 2018 Mar;81(3):461-468. doi: 10.1007/s00280-017-3513-4. Epub 2018 Jan 5. Cancer Chemother Pharmacol. 2018. PMID: 29305639 Clinical Trial.
Phase I study of adjuvant chemotherapy with gemcitabine plus cisplatin in patients with biliary tract cancer undergoing curative resection without major hepatectomy (KHBO1004).
Toyoda M, Ajiki T, Fujiwara Y, Nagano H, Kobayashi S, Sakai D, Hatano E, Kanai M, Nakamori S, Miyamoto A, Tsuji A, Kaihara S, Ikoma H, Takemura S, Toyokawa H, Terajima H, Morita S, Ioka T. Toyoda M, et al. Among authors: toyokawa h. Cancer Chemother Pharmacol. 2014 Jun;73(6):1295-301. doi: 10.1007/s00280-014-2431-y. Epub 2014 Mar 11. Cancer Chemother Pharmacol. 2014. PMID: 24614947 Free PMC article. Clinical Trial.
Patients with recurrent biliary tract cancer have a better prognosis than those with unresectable disease: retrospective analysis of a multi-institutional experience with patients of advanced biliary tract cancer who received palliative chemotherapy.
Ikezawa K, Kanai M, Ajiki T, Tsukamoto T, Toyokawa H, Terajima H, Furuyama H, Nagano H, Ikai I, Kuroda N, Awane M, Ochiai T, Takemura S, Miyamoto A, Kume M, Ogawa M, Takeda Y, Taira K, Ioka T. Ikezawa K, et al. Among authors: toyokawa h. J Hepatobiliary Pancreat Sci. 2014 Feb;21(2):98-104. doi: 10.1002/jhbp.2. Epub 2013 Jun 20. J Hepatobiliary Pancreat Sci. 2014. PMID: 23798367
Comparative outcomes of elderly and non-elderly patients receiving first-line palliative chemotherapy for advanced biliary tract cancer.
Kou T, Kanai M, Ikezawa K, Ajiki T, Tsukamoto T, Toyokawa H, Yazumi S, Terajima H, Furuyama H, Nagano H, Ikai I, Kuroda N, Awane M, Ochiai T, Takemura S, Miyamoto A, Kume M, Ogawa M, Takeda Y, Taira K, Ioka T. Kou T, et al. Among authors: toyokawa h. J Gastroenterol Hepatol. 2014 Feb;29(2):403-8. doi: 10.1111/jgh.12338. J Gastroenterol Hepatol. 2014. PMID: 23869919
122 results